HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2016-11-22FDA Approved: NORVIR — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for NORVIR (ritonavir) submitted by AbbVie.
-
FDA approval · 2016-11-22FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) submitted by AbbVie's AbbVie Inc.
-
FDA approval · 2016-11-22FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) from AbbVie, updating the product labeling as a result of the subm…
-
FDA approval · 2016-11-21FDA Approved: LAMIVUDINE — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original ANDA for lamivudine, enabling a generic version of lamivudine to be marketed.
-
FDA approval · 2016-11-21FDA Approved: LAMIVUDINE — Original Application (Ingenus Pharmaceuticals, LLC)
The FDA approved a generic lamivudine product under an Original Application filed by Ingenus Pharmaceuticals, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-11-21FDA Approved: LAMIVUDINE — Original Application (Rising Pharma Holdings, Inc.)
FDA approved the original generic application for lamivudine from Rising Pharma Holdings, Inc., making a generic option available for HIV-1 …
-
FDA approval · 2016-11-08FDA Approved: TIVICAY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for Tivicay (dolutegravir) submitted by ViiV Healthcare Company, authorizing changes to the product …
-
FDA approval · 2016-11-04FDA Approved: SELZENTRY — Original Application (ViiV Healthcare Company)
FDA approves SELZENTRY (maraviroc) under the original application for treatment of HIV-1 infection.
-
FDA approval · 2016-11-04FDA Approved: SELZENTRY — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for SELZENTRY (maraviroc) submitted by ViiV Healthcare Company.
-
FDA approval · 2016-09-26FDA Approved: ABACAVIR — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Abacavir from Camber Pharmaceuticals, resulting in labeling changes for the product.
-
FDA approval · 2016-09-26FDA Approved: ABACAVIR — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic abacavir under an Original Application (ANDA) for HIV-1 infection.
-
FDA approval · 2016-09-15FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
FDA approved a supplemental application for Kaletra (lopinavir/ritonavir) submitted by AbbVie.
-
FDA approval · 2016-09-15FDA Approved: APTIVUS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for APTIVUS (tipranavir) from Boehringer Ingelheim Pharmaceuticals, Inc., resulting in changes to th…
-
FDA approval · 2016-09-15FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for Reyataz (atazanavir) submitted by E.R. Squibb & Sons, L.L.C.
-
FDA approval · 2016-09-15FDA Approved: KALETRA — Supplemental Application (AbbVie Inc.)
The FDA approved a supplemental application for KALETRA (lopinavir/ritonavir) submitted by AbbVie Inc.
-
FDA approval · 2016-09-15FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Prezista (darunavir) submitted by Janssen Products LP.
-
FDA approval · 2016-09-15FDA Approved: STRIBILD — Supplemental Application (Gilead Sciences, Inc.)
FDA approved the supplemental application for STRIBILD (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate) from Gil…
-
FDA approval · 2016-09-15FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)
The FDA approved a supplemental application for Reyataz (atazanavir) from E.R. Squibb & Sons, L.L.C., updating its labeling and/or indicatio…
-
FDA approval · 2016-09-15FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) submitted by Gi…
-
FDA approval · 2016-09-15FDA Approved: PREZISTA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Prezista (darunavir) from Janssen Products LP.
-
FDA approval · 2016-09-15FDA Approved: VIRACEPT — Supplemental Application (AGOURON)
FDA approved a supplemental application for Viracept (nelfinavir mesylate) submitted by Agouron.
-
FDA approval · 2016-09-15FDA Approved: VIRACEPT — Supplemental Application (AGOURON)
FDA approved a supplemental application for Viracept (nelfinavir mesylate) submitted by Agouron.
-
FDA approval · 2016-09-07FDA Approved: GENVOYA — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) from Gilead Sci…
-
EMA approval · 2016-07-22First medicine for HIV pre-exposure prophylaxis recommended for approval in the EU
The EU medicines agency recommends approval of the first medicine for HIV pre-exposure prophylaxis (PrEP) in the European Union.
-
FDA approval · 2016-07-20FDA Approved: EPIVIR — Supplemental Application (ViiV Healthcare Company)
FDA approved a supplemental application for EPIVIR (lamivudine) submitted by ViiV Healthcare Company.